The numbers are in, and biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past.
Venture-backed biopharma companies raised $6.8 billion in the first three months of the year, according to early data compiled by HSBC. That’s the largest amount raised since the first half of 2022.
That’s big news for an industry that has been icy for the last three years, once the attention the Covid pandemic brought to drug companies began to fade. Layoffs became commonplace. Landlords in places like greater Boston suddenly found they had vacant labs for the first time in a decade.
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.